ANN ARBOR, MI / ACCESSWIRE / November 2, 2023 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Monday, November 13, 2023 at 4:30 p.m. ET to discuss the Company’s operational and financial highlights for its third quarter ended September 30, 2023. A question-and-answer session will follow management’s prepared remarks.
Event: Zomedica Q3 2023 Financial Results Conference Call
Date: Monday, November 13, 2023
Time: 4:30 p.m. Eastern Time
Live Call: +1-877-407-0789 (U.S. Toll-Free) or +1-201-689-8562 (International)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1641216&tp_key=4fcf4cae49
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Monday, November 27, 2023 at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 13742390.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica’s mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
Twitter: https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View source version on accesswire.com:
https://www.accesswire.com/798109/zomedica-to-report-third-quarter-2023-financial-results-and-provide-business-update-on-november-13-at-430-pm-et
NEW YORK CITY, NY / ACCESS Newswire / January 10, 2026 / The phrase best…
CES Official Spokesperson Highlights UOG Featured ProductsIntroducing the World's First Black Diamond Carbon & Nano…
Independent research summary reviews mechanisms, regulatory considerations, and telehealth access pathways as consumers compare growth…
Examining Akkermansia Muciniphila, Clostridium Butyricum, And The Gut Microbiome Research Behind This Probiotic GLP-1 Supplement…
Independent Analysis Examines MEDVi's Semaglutide Medication Model, FDA Compounding Framework, and Prescription Accessibility Trends Heading…
Published NAD+ research examines cellular aging pathways and mitochondrial function as prescription peptide injection access…